Clinical tools for oncology professionals
Home
Topics
Acute Oncology
Breast oncology
CNS oncology
Genetics
GI oncology
Gynae oncology
Hemato-oncology
Head and Neck oncology
Lung oncology
Palliative care
Pharmacology
Surgical oncology
Uro-oncology
All tools
About
Terms of use
Contact
About us
Latest tools
HFA-ICOS Cardio-Oncology Cardiovascular Risk Assessment tool
Stratifies the risk of cancer treatment related cardiovascular toxicity at baseline according to planned therapy and patient related factors.
Immunotherapy toxicity management tool
Summarises management of immunotherapy toxicities according to international society guidelines
Tumor Lysis Syndrome (TLS) risk assessment tool
Stratifies patients into low, intermediate or high risk for developing TLS and guides prophylaxis.
GIST (Gastrointestinal Stromal Tumor) recurrence risk calculator
Estimates risk of recurrence in resected GISTs.
Immune effector Cell Associated Neurotoxicity Syndrome (ICANS) grade (ASTCT criteria)
Grades severity of ICANS according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
Cytokine Release Syndrome (CRS) Grade (ASTCT criteria)
Grades severity of CRS syndrome according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
DPYD (DPD) Activity Score Calculator (CPIC guidelines)
Provides information on functional impact of DPYD (DPD) variants and genotype guided dosing advice for fluoropyrimidine chemotherapy.
RECIST 1.1
The RECIST criteria are used to assess radiological response to cancer therapy in solid tumours.
ESMO-MCBS: ESMO Magnitude of Clinical Benefit Scale tool v1.1
Assesses the value of a new cancer therapy, taking into account the magnitude of clinical benefit, toxicity and cost within a reproducible scale.
Mirels score
Assesses risk of pathological fracture in patients with a long bone metastasis.
IPI, R-IPI and NCCN-IPI scores for DLBCL
The International Prognostic Index (IPI), revised IPI (R-IPI) and NCCN-IPI are prognostic tools used to predict survival in patients with DLBCL (diffuse large B cell lymphoma).
Early stage Hodgkin’s lymphoma risk stratification tool
Risk stratifies early stage Hodgkin’s lymphoma according to the EORTC, GHSG or NCCN criteria.
Hasenclever International Prognostic Score (IPS) for advanced stage classical Hodgkin's lymphoma
Risk stratifies advanced stage Hodgkin’s lymphoma into 6 prognostic groups.
Graded Prognostic Assessment (GPA)
Estimates survival in patients with brain metastases.
Pulmonary nodule malignancy risk tools
Assess the malignancy risk of pulmonary nodules. Includes both the Herder and Brock models.
CISNE (Clinical Index of Stable febrile Neutropenia) risk tool
Used to identify patients with chemotherapy related febrile neutropenia who are low risk for medical complications.
MASCC (Multinational Association for Supportive Care in Cancer risk index) score
Used to identify patients with chemotherapy related febrile neutropenia who are low risk for medical complications.
Opioid conversion calculator
Calculates the equi-analgesic dose of a given opioid according to desired opioid drug and route of administration.
Carboplatin dosing (Calvert formula)
Calculates the dose of carboplatin based on glomerular filtration rate and target AUC.
Spinal Instability Neoplastic Score (SINS)
Assesses spinal instability in the vertebral column in patients with neoplastic spinal disease.
Body Surface Area (BSA) calculator
Calculates body surface area using height and weight.
Anthracycline total exposure calculator
Calculates total anthracycline exposure based on equivalent dose of each anthracycline received.
CARG
Predicts risk of severe chemotherapy toxicity (grade 3-5) in older patients aged over 65.
CARG-BC
Predicts risk of severe chemotherapy toxicity (grade 3-5) in patients aged over 65 with early stage breast cancer.
Daily Chemotherapy Toxicity self Assessment Questionnaire (DCTAQ)
A patient reported outcome tool for self-reporting chemotherapy toxicities.
Manchester score with pathology adjustment
Predicts finding a pathogenic germline BRCA1/BRCA2 mutation in families with suspected hereditary breast or ovarian cancer.